ArticleJournal of chemical information and modeling2026
SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutic monoclonal antibody bebtelovimab (BEB) was designed to target the spike protein of SARS-CoV-2 and block its entry into host cells via the angiotensin-converting enzyme 2 (ACE2) receptor. In this study, we used molecular modeling to predict interactions of six clinically observed viral S-protein mutants with human ACE2, as well as BEB. We found that some of these mutants could reduce the activity of BEB by changing the relative binding affinity of the viral S-protein with BEB and ACE2. This may contribute to the resistance in viral mutants to BEB. Additionally, we demonstrated that this effect is highly dependent on the dynamic behavior of the involved proteins and their structural variations. We further assessed BEB's activity against SARS-CoV-2 Omicron subvariants BQ.1 and BQ.1.1. Our study provides insights into how mutations may affect BEB's activity, offering valuable information for the development of future therapeutics against rapidly mutating pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.